V van der Noort
Overview
Explore the profile of V van der Noort including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verkerk K, Zeverijn L, van de Haar J, Roepman P, Geurts B, Spiekman A, et al.
ESMO Open
. 2025 Jan;
10(1):104112.
PMID: 39778224
Background: Many patients with cancer exhibit primary or rapid secondary resistance to targeted therapy (TT). We hypothesized that a higher number of altered oncogenic signaling pathways [pathway alteration load (PAL)]...
2.
van der Wel J, Jebbink M, van den Broek D, Steinbusch L, Theelen W, Ruiter G, et al.
Lung Cancer
. 2024 Nov;
198:107972.
PMID: 39556978
Introduction: Osimertinib resistance inevitably occurs in EGFR mutated NSCLC. We aimed to identify resistance mechanisms (RM) using paired plasma and tumor samples in patients that progressed on 2nd/3rd line osimertinib....
3.
Schouten R, Schouten I, Schuurbiers M, van der Noort V, Damhuis R, van der Heijden E, et al.
PLoS One
. 2024 Jul;
19(7):e0290939.
PMID: 39083479
Introduction: Molecular profiling of NSCLC is essential for optimising treatment decisions, but often incomplete. We assessed the efficacy of protocolised molecular profiling in the current standard-of-care (SoC) in a prospective...
4.
van der Zande K, Tutuhatunewa-Louhanepessy R, Hamberg P, Ras S, de Feijter J, Dezentje V, et al.
Clin Genitourin Cancer
. 2024 Jan;
22(2):445-453.e1.
PMID: 38246830
Background: There is new interest in platinum-based treatment of patients with metastatic castration resistant prostate cancer (mCRPC), to which a subgroup responds. Although platinum sensitivity is suggested to be associated...
5.
Dumoulin D, Douma L, Hofman M, van der Noort V, Cornelissen R, de Gooijer C, et al.
Lung Cancer
. 2023 Dec;
187:107440.
PMID: 38104353
Objectives: Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab improved the survival, however, 30.3% of the patients suffered from grade 3-4...
6.
Hagens M, Ribbert L, Jager A, Veerman H, Barwari K, Boodt B, et al.
Prostate Cancer Prostatic Dis
. 2023 Sep;
27(2):312-317.
PMID: 37660218
Background: This study aimed to evaluate the histopathological concordance rates between prostate biopsies and radical prostatectomy specimens according to the applied biopsy approach (transrectal or transperineal). Methods: We studied patients...
7.
Jebbink M, de Langen A, Monkhorst K, Boelens M, van den Broek D, van der Noort V, et al.
JTO Clin Res Rep
. 2023 Apr;
4(4):100481.
PMID: 37035409
Introduction: tyrosine kinase inhibitor improved the survival of patients with metastatic mutation-positive () NSCLC. Despite high response rates, resistance develops inevitably in every patient. In up to 13%, protein overexpression...
8.
van Berge Henegouwen J, Jebbink M, Hoes L, van der Wijngaart H, Zeverijn L, van der Velden D, et al.
Eur J Cancer
. 2022 Jun;
171:114-123.
PMID: 35716537
Introduction: In 1-3% of non-small cell lung cancer (NSCLC) human epidermal growth factor 2 (HER2) mutations are identified as a genomic driver. Nevertheless, no HER2-targeted treatment is approved for NSCLC....
9.
Lof P, van de Vrie R, Korse C, van Gent M, Mom C, Rosier-van Dunne F, et al.
Gynecol Oncol
. 2022 Jun;
166(2):284-291.
PMID: 35688656
Introduction: The value of serum human epididymis protein 4 (HE4) in guiding referral decisions in patients with an ovarian mass remains unclear, because the majority of studies investigating HE4 were...
10.
Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, et al.
Breast Cancer Res Treat
. 2022 May;
194(2):265-278.
PMID: 35587322
Purpose: Guidelines recommend endocrine treatment for estrogen receptor-positive (ER+) breast cancers for up to 10 years. Earlier data suggest that the 70-gene signature (MammaPrint) has potential to select patients that...